Durvalumab

Durvalumab is administered as an intravenous (IV) infusion in a hospital or clinic under healthcare provider supervision.

The treatment duration with Durvalumab varies based on cancer type, treatment response, and overall health, and will be determined by your doctor.

Durvalumab is used to treat non-small cell lung cancer (NSCLC), biliary tract cancer, liver cancer, and endometrial cancer, particularly in advanced or unresectable cases.

Inform your doctor about all medications and supplements you are taking, as Durvalumab may interact with other drugs.

During treatment, you may experience side effects such as fatigue, cough, or loss of appetite. Report any severe symptoms to your doctor immediately.

Avoid infections, report unusual symptoms, and discuss your medical history with your doctor, especially regarding autoimmune conditions, pregnancy, or breastfeeding.